Alana L Welm

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3071465/publications.pdf

Version: 2024-02-01

77	7,455	76326	74163
papers	citations	40 h-index	75 g-index

84	84	84	12668
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nature Medicine, 2011, 17, 1514-1520.	30.7	842
2	Transient Low Doses of DNA-Demethylating Agents Exert Durable Antitumor Effects on Hematological and Epithelial Tumor Cells. Cancer Cell, 2012, 21, 430-446.	16.8	564
3	Protective autophagy elicited by RAFâ†'MEKâ†'ERK inhibition suggests a treatment strategy for RAS-driven cancers. Nature Medicine, 2019, 25, 620-627.	30.7	457
4	A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds. Cell, 2016, 167, 260-274.e22.	28.9	376
5	C/EBPÎ± Arrests Cell Proliferation through Direct Inhibition of Cdk2 and Cdk4. Molecular Cell, 2001, 8, 817-828.	9.7	312
6	Understanding the Bone in Cancer Metastasis. Journal of Bone and Mineral Research, 2018, 33, 2099-2113.	2.8	285
7	RNA CUG Repeats Sequester CUGBP1 and Alter Protein Levels and Activity of CUGBP1. Journal of Biological Chemistry, 2001, 276, 7820-7826.	3.4	266
8	The lingering mysteries of metastatic recurrence in breast cancer. British Journal of Cancer, 2021, 124, 13-26.	6.4	263
9	The Six1 homeoprotein induces human mammary carcinoma cells to undergo epithelial-mesenchymal transition and metastasis in mice through increasing TGF-Î² signaling. Journal of Clinical Investigation, 2009, 119, 2678-2690.	8.2	209
10	Metabolic reprogramming in triple-negative breast cancer through Myc suppression of TXNIP. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 5425-5430.	7.1	190
11	Patient-derived xenograft (PDX) models in basic and translational breast cancer research. Cancer and Metastasis Reviews, 2016, 35, 547-573.	5.9	189
12	Cell division and cell survival in the absence of survivin. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 15100-15105.	7.1	172
13	Lentiviral Transduction of Mammary Stem Cells for Analysis of Gene Function during Development and Cancer. Cell Stem Cell, 2008, 2, 90-102.	11.1	171
14	Patientâ€Derived Models of Human Breast Cancer: Protocols for In Vitro and In Vivo Applications in Tumor Biology and Translational Medicine. Current Protocols in Pharmacology, 2013, 60, Unit14.23.	4.0	162
15	Six1 expands the mouse mammary epithelial stem/progenitor cell pool and induces mammary tumors that undergo epithelial-mesenchymal transition. Journal of Clinical Investigation, 2009, 119, 2663-2677.	8.2	153
16	A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology. Nature Cancer, 2022, 3, 232-250.	13.2	133
17	The macrophage-stimulating protein pathway promotes metastasis in a mouse model for breast cancer and predicts poor prognosis in humans. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 7570-7575.	7.1	126
18	Protein Arginine Methyltransferase 5 Accelerates Tumor Growth by Arginine Methylation of the Tumor Suppressor Programmed Cell Death 4. Cancer Research, 2011, 71, 5579-5587.	0.9	126

#	Article	IF	Citations
19	Invasive Lobular Carcinoma Cell Lines Are Characterized by Unique Estrogen-Mediated Gene Expression Patterns and Altered Tamoxifen Response. Cancer Research, 2014, 74, 1463-1474.	0.9	122
20	Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts. Nature Genetics, 2021, 53, 86-99.	21.4	118
21	Functional precision oncology: Testing tumors with drugs to identify vulnerabilities and novel combinations. Cancer Cell, 2022, 40, 26-35.	16.8	108
22	C/EBPÎ± Regulates Generation of C/EBPÎ² Isoforms through Activation of Specific Proteolytic Cleavage. Molecular and Cellular Biology, 1999, 19, 1695-1704.	2.3	102
23	HOXA9 regulates BRCA1 expression to modulate human breast tumor phenotype. Journal of Clinical Investigation, 2010, 120, 1535-1550.	8.2	98
24	PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models. Cancer Research, 2017, 77, e62-e66.	0.9	92
25	Calreticulin Interacts with C/EBPÎ± and C/EBPÎ² mRNAs and Represses Translation of C/EBP Proteins. Molecular and Cellular Biology, 2002, 22, 7242-7257.	2.3	90
26	Coordinate expression and functional profiling identify an extracellular proteolytic signaling pathway. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 5771-5776.	7.1	89
27	MET and MYC cooperate in mammary tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 4324-4329.	7.1	87
28	Tumoural activation of TLR3â€“SLIT2 axis in endothelium drives metastasis. Nature, 2020, 586, 299-304.	27.8	84
29	The EWS/FLI Oncogene Drives Changes in Cellular Morphology, Adhesion, and Migration in Ewing Sarcoma. Genes and Cancer, 2012, 3, 102-116.	1.9	82
30	Netrin-4 induces lymphangiogenesis in vivo. Blood, 2010, 115, 5418-5426.	1.4	78
31	Inhibition of Ron Kinase Blocks Conversion of Micrometastases to Overt Metastases by Boosting Antitumor Immunity. Cancer Discovery, 2013, 3, 751-760.	9.4	69
32	Treatment of Triple-Negative Breast Cancer Using Anti-EGFRâ€“Directed Radioimmunotherapy Combined with Radiosensitizing Chemotherapy and PARP Inhibitor. Journal of Nuclear Medicine, 2013, 54, 913-921.	5.0	66
33	Preclinical Evaluation of Fatty Acid Synthase and EGFR Inhibition in Triple-Negative Breast Cancer. Clinical Cancer Research, 2016, 22, 4687-4697.	7.0	62
34	RON kinase: A target for treatment of cancer-induced bone destruction and osteoporosis. Science Translational Medicine, 2017, 9, .	12.4	58
35	Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment. Nature Communications, 2021, 12, 5086.	12.8	58
36	Loss of RasGAP Tumor Suppressors Underlies the Aggressive Nature of Luminal B Breast Cancers. Cancer Discovery, 2017, 7, 202-217.	9.4	57

#	Article	IF	Citations
37	The Macrophage Stimulating Protein/Ron Pathway as a Potential Therapeutic Target to Impede Multiple Mechanisms Involved in Breast Cancer Progression. Current Drug Targets, 2010, 11, 1157-1168.	2.1	52
38	Astrocytic laminin-211 drives disseminated breast tumor cell dormancy in brain. Nature Cancer, 2022, 3, 25-42.	13.2	52
39	The RON Receptor Tyrosine Kinase Promotes Metastasis by Triggering MBD4-Dependent DNA Methylation Reprogramming. Cell Reports, 2014, 6, 141-154.	6.4	48
40	Phosphorylation of the src Epithelial Substrate Trask Is Tightly Regulated in Normal Epithelia but Widespread in Many Human Epithelial Cancers. Clinical Cancer Research, 2009, 15, 2311-2322.	7.0	46
41	Short-Form Ron Promotes Spontaneous Breast Cancer Metastasis through Interaction with Phosphoinositide 3-Kinase. Genes and Cancer, 2011, 2, 753-762.	1.9	41
42	Netrin-4 Activates Endothelial Integrin Î±6Î²1. Circulation Research, 2011, 109, 770-774.	4.5	40
43	Translational Induction of Liver-enriched Transcriptional Inhibitory Protein during Acute Phase Response Leads to Repression of CCAAT/Enhancer Binding Protein Î± mRNA. Journal of Biological Chemistry, 2000, 275, 27406-27413.	3.4	39
44	Blocking Fibroblast Growth Factor Receptor Signaling Inhibits Tumor Growth, Lymphangiogenesis, and Metastasis. PLoS ONE, 2012, 7, e39540.	2.5	39
45	High Intratumoral Stromal Content Defines Reactive Breast Cancer as a Low-risk Breast Cancer Subtype. Clinical Cancer Research, 2016, 22, 5068-5078.	7.0	38
46	Dll1+ quiescent tumor stem cells drive chemoresistance in breast cancer through NF-Î²B survival pathway. Nature Communications, 2021, 12, 432.	12.8	38
47	Proapoptotic PUMA targets stem-like breast cancer cells to suppress metastasis. Journal of Clinical Investigation, 2017, 128, 531-544.	8.2	38
48	Survivin promotion of melanoma metastasis requires upregulation of Î± 5 integrin. Carcinogenesis, 2013, 34, 2137-2144.	2.8	36
49	Preclinical Efficacy of Ron Kinase Inhibitors Alone and in Combination with PI3K Inhibitors for Treatment of sfRon-Expressing Breast Cancer Patient-Derived Xenografts. Clinical Cancer Research, 2015, 21, 5588-5600.	7.0	32
50	EPHB6 augments both development and drug sensitivity of triple-negative breast cancer tumours. Oncogene, 2018, 37, 4073-4093.	5.9	30
51	A Dominant Mutant Allele of the ING4 Tumor Suppressor Found in Human Cancer Cells Exacerbates MYC-Initiated Mouse Mammary Tumorigenesis. Cancer Research, 2010, 70, 5155-5162.	0.9	29
52	C/EBPÎ± Is Required for Proteolytic Cleavage of Cyclin A by Calpain 3 in Myeloid Precursor Cells. Journal of Biological Chemistry, 2002, 277, 33848-33856.	3.4	28
53	TGFÎ² Primes Breast Tumor Cells for Metastasis. Cell, 2008, 133, 27-28.	28.9	26
54	Mouse models of breast cancer metastasis to bone. Cancer and Metastasis Reviews, 2012, 31, 579-583.	5.9	26

#	Article	IF	Citations
55	Inhibition of RON kinase potentiates anti-CTLA-4 immunotherapy to shrink breast tumors and prevent metastatic outgrowth. OncoImmunology, 2018, 7, e1480286.	4.6	23
56	Overview of Human Primary Tumorgraft Models: Comparisons with Traditional Oncology Preclinical Models and the Clinical Relevance and Utility of Primary Tumorgrafts in Basic and Translational Oncology Research. Current Protocols in Pharmacology, 2012, 59, Unit 14.22.	4.0	21
57	RON promotes the metastatic spread of breast carcinomas by subverting antitumor immune responses. OncoImmunology, 2013, 2, e25670.	4.6	21
58	RON Signaling Is a Key Mediator of Tumor Progression in Many Human Cancers. Cold Spring Harbor Symposia on Quantitative Biology, 2016, 81, 177-188.	1.1	21
59	NetH2pan: A Computational Tool to Guide MHC Peptide Prediction on Murine Tumors. Cancer Immunology Research, 2018, 6, 636-644.	3.4	20
60	mTORC1 is a key mediator of RON-dependent breast cancer metastasis with therapeutic potential. Npj Breast Cancer, 2018, 4, 36.	5.2	20
61	An immune-humanized patient-derived xenograft model of estrogen-independent, hormone receptor positive metastatic breast cancer. Breast Cancer Research, 2021, 23, 100.	5.0	20
62	RON signalling promotes therapeutic resistance in ESR1 mutant breast cancer. British Journal of Cancer, 2021, 124, 191-206.	6.4	16
63	Short-form Ron is a novel determinant of ovarian cancer initiation and progression. Genes and Cancer, 2016, 7, 169-181.	1.9	15
64	The importance of developing therapies targeting the biological spectrum of metastatic disease. Clinical and Experimental Metastasis, 2019, 36, 305-309.	3.3	9
65	Singleâ€cell RNA sequencing reveals localized tumour ablation and intratumoural immunostimulant delivery potentiate T cell mediated tumour killing. Clinical and Translational Medicine, 2022, 12, .	4.0	9
66	A pipeline for identification and validation of tumor-specific antigens in a mouse model of metastatic breast cancer. OncoImmunology, 2020, 9, 1685300.	4.6	8
67	On the shoulders of giants: A historical perspective of unique experimental methods in mammary gland research. Seminars in Cell and Developmental Biology, 2012, 23, 583-590.	5.0	7
68	Toward improved models of human cancer. APL Bioengineering, 2021, 5, 010901.	6.2	7
69	Blocking Short-Form Ron Eliminates Breast Cancer Metastases through Accumulation of Stem-Like CD4+ T Cells That Subvert Immunosuppression. Cancer Discovery, 2021, 11, 3178-3197.	9.4	7
70	PDXNet portal: patient-derived Xenograft model, data, workflow and tool discovery. NAR Cancer, 2022, 4, zcac014.	3.1	7
71	Ligandâ€based Discovery of Novel Small Molecule Inhibitors of RON Receptor Tyrosine Kinase. Molecular Informatics, 2022, 41, .	2.5	4
72	Enrichment of Collagen Fragments Using Dimeric Collagen Hybridizing Peptide for Urinary Collagenomics. Journal of Proteome Research, 2020, 19, 2926-2932.	3.7	4

#	Article	IF	Citations
73	Abstract 1673: Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts. , 2020, , .		3
74	O43 Therapeutic vaccination against breast cancer in a transgenic mouse model. Human Immunology, 2017, 78, 40.	2.4	0
75	Heterogeneity in Metastatic Potential of Cancer Cells Is Revealed En Masse. Cancer Cell, 2021, 39, 148-150.	16.8	0
76	CD229 CAR T Cell Therapy for the Treatment of Relapsed B Cell Lymphoma. Blood, 2021, 138, 2800-2800.	1.4	0
77	Improving the odds together: a framework for breast cancer research scientists to include patient advocates in their research. Npj Breast Cancer, 2022, 8, .	5.2	0